ABSTRACT
BACKGROUND: Infections caused by KPC-producing Klebsiella pneumoniae (Kp) are associated with high mortality. Therefore, new treatment options are urgently required. OBJECTIVES: To assess the outcomes and predictors of mortality in patients with KPC- or OXA-48-Kp infections treated with ceftazidime/avibactam with an emphasis on KPC-Kp bloodstream infections (BSIs). METHODS: A multicentre prospective observational study was conducted between January 2018 and March 2019. Patients with KPC- or OXA-48-Kp infections treated with ceftazidime/avibactam were included in the analysis. The subgroup of patients with KPC-Kp BSIs treated with ceftazidime/avibactam was matched by propensity score with a cohort of patients whose KPC-Kp BSIs had been treated with agents other than ceftazidime/avibactam with in vitro activity. RESULTS: One hundred and forty-seven patients were identified; 140 were infected with KPC producers and 7 with OXA-48 producers. For targeted therapy, 68 (46.3%) patients received monotherapy with ceftazidime/avibactam and 79 (53.7%) patients received ceftazidime/avibactam in combination with at least another active agent. The 14 and 28 day mortality rates were 9% and 20%, respectively. The 28 day mortality among the 71 patients with KPC-Kp BSIs treated with ceftazidime/avibactam was significantly lower than that observed in the 71 matched patients, whose KPC-Kp BSIs had been treated with agents other than ceftazidime/avibactam (18.3% versus 40.8%; P = 0.005). In the Cox proportional hazards model, ultimately fatal disease, rapidly fatal disease and Charlson comorbidity index ≥2 were independent predictors of death, whereas treatment with ceftazidime/avibactam-containing regimens was the only independent predictor of survival. CONCLUSIONS: Ceftazidime/avibactam appears to be an effective treatment against serious infections caused by KPC-Kp.
Subject(s)
Anti-Bacterial Agents , Azabicyclo Compounds , Ceftazidime , Klebsiella Infections , Klebsiella pneumoniae , Anti-Bacterial Agents/therapeutic use , Azabicyclo Compounds/therapeutic use , Bacterial Proteins , Ceftazidime/therapeutic use , Drug Combinations , Humans , Klebsiella Infections/drug therapy , Klebsiella Infections/mortality , Microbial Sensitivity Tests , Registries , beta-LactamasesABSTRACT
We report our experience using the double-carbapenem combination as salvage therapy for patients with untreatable infections caused by KPC-2- producing Klebsiella pneumoniae. A total of 27 patients in two institutions in Athens, Greece suffering from complicated urinary tract infections (16) with or without secondary bacteraemia (four and 12 respectively), primary (six) or catheter-related bloodstream infections (two), HAP or VAP (two) and external ventricular drainage infection (one) were treated exclusively with ertapenem and high-dose prolonged infusion meropenem because in-vitro active antimicrobials were unavailable (19) or failed (four) or were contraindicated (six). Most patients presented with severe infections with median APACHE II score of 17 and 11 of those patients (40.7%) had severe sepsis (five) or septic shock (six). The clinical and microbiological success was 77.8 and 74.1% respectively. Crude mortality was 29.6% with attributable mortality of 11.1%. Adverse events, none of them severe, were reported in four patients (14.8%). The double-carbapenem combination as an exclusive regimen represents a safe and valid salvage therapy for untreatable infections by extensively- or pandrug-resistant KPC-producing K.pneumoniae.
Subject(s)
Anti-Bacterial Agents/administration & dosage , Carbapenems/administration & dosage , Klebsiella Infections/drug therapy , Klebsiella pneumoniae/enzymology , Salvage Therapy/methods , beta-Lactamases/metabolism , Adolescent , Adult , Aged , Aged, 80 and over , Bacteremia/drug therapy , Bacteremia/microbiology , Catheter-Related Infections/drug therapy , Catheter-Related Infections/microbiology , Female , Greece , Humans , Klebsiella Infections/microbiology , Klebsiella pneumoniae/isolation & purification , Male , Meropenem , Middle Aged , Prospective Studies , Thienamycins/administration & dosage , Treatment Outcome , Urinary Tract Infections/complications , Urinary Tract Infections/drug therapy , Urinary Tract Infections/microbiology , Young AdultABSTRACT
A cohort study of patients (pts) presenting with symptoms of chronic prostatitis over 2 years was performed. Appropriate antimicrobials were administered to confirmed cases of chronic bacterial prostatitis (CBP) after a Stamey-meares (S-M) test for a period of 6 weeks and the test was repeated 1 and 6 months post therapy completion. 145 male patients presented for evaluation. the most prevalent symptoms included dysuria (68%), frequency (38%), and pain which was present in 50%. S-M testing was performed in 69% and expressed prostatic specimen was collected in 53.8%. the diagnosis of CBP was established in 26.9% of the total cohort. Escherichia coli (28.2%) and Enterococcus spp (23.1%) were the most frequently implicated pathogens and ciprofloxacin the most commonly prescribed antimicrobial. A 12-month follow-up was completed in 87% of the pts and 35.3% relapsed a mean of 4.75 months after the initial treatment.
Subject(s)
Anti-Infective Agents/therapeutic use , Fluoroquinolones/therapeutic use , Prostatitis/drug therapy , Adult , Ciprofloxacin/therapeutic use , Cohort Studies , Humans , Male , Middle Aged , Prospective Studies , Prostatitis/diagnosisABSTRACT
Vancomycin-resistant enterococci (VRE) have emerged as significant nosocomial pathogens. A hospital-wide prevalence study was performed to identify cases with VRE faecal colonisation. A case-control study using two randomly selected VRE-negative controls for each positive case was performed to assess risk-factors for VRE colonisation by univariate and multivariate analysis. VRE faecal colonisation was documented in 53 (14.3%) of 370 patients screened. Previous exposure to anti-anaerobic agents, as well as quinolones, was associated with VRE colonisation (p <0.05). The presence of an invasive device (OR 4.8, p 0.003) and the duration of any antimicrobial treatment before VRE isolation (OR 1.2, p <0.001) predicted VRE colonisation in multivariate models. The crude mortality rate for patients with VRE colonisation was 24.5%, but VRE colonisation was not an independent predictor of mortality in these patients. These results suggest that an active surveillance programme focusing on specific patient groups may help in the identification of VRE-colonised patients. Promptly implemented infection control strategies targeting these groups should help to combat the rising incidence of VRE.
Subject(s)
Cross Infection/microbiology , Cross Infection/mortality , Enterococcus/drug effects , Gram-Positive Bacterial Infections/microbiology , Gram-Positive Bacterial Infections/mortality , Vancomycin Resistance , Aged , Anti-Bacterial Agents/therapeutic use , Case-Control Studies , Cross Infection/epidemiology , Enterococcus/isolation & purification , Feces/microbiology , Female , Gram-Positive Bacterial Infections/epidemiology , Humans , Male , Middle Aged , Multivariate Analysis , Prevalence , Risk Factors , Time FactorsABSTRACT
In order to assess the diagnostic value of procalcitonin, 158 patients with febrile neutropenia from centres across Europe were studied. Patients with fever were diagnosed on the basis of either: (1) clinical, radiological and microbiological criteria; or (2) the procalcitonin value. In the latter case, concentrations of 0.5-1.0 ng/mL were considered diagnostic of localised infection, concentrations of 1.0-5.0 ng/mL of bacteraemia, and concentrations of > 5.0 ng/mL of severe sepsis. Procalcitonin and C-reactive protein were estimated daily in serum by immunochemiluminescence and nephelometry, respectively. Overall, the sensitivity (specificity) of procalcitonin for bacteraemia was 44.2% (64.3%) at concentrations of 1.0-5.0 ng/mL, and 83.3% (100%) for severe sepsis at concentrations of > 5.0 ng/mL. It was concluded that procalcitonin is a marker strongly suggestive of severe sepsis at concentrations of > 5.0 ng/mL. Estimated concentrations of < 0.5 ng/mL indicate that infection is unlikely, but it was observed that bacteraemia associated with coagulase-negative staphylococci may fail to elevate serum procalcitonin levels.